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ABSTRACT 41 
Purpose: Evidence from studies mainly in children has shown that orally 42 
administered probiotics may prevent respiratory tract infections and associated 43 
antibiotic use [1]. We evaluated whether advice to take daily probiotics can reduce 44 
antibiotic prescribing for winter respiratory infections in people with asthma. 45 
Methods: This was a randomized controlled, parallel-group pragmatic study for 46 
participants aged ≥5 years with asthma in a UK primary care setting. The 47 
intervention was a postal leaflet with advice to take daily probiotics (Lab4, Cultech, 48 
Swansea) from October 2013 to March 2014, compared to a standard winter advice 49 
leaflet. Primary outcome was the proportion of participants prescribed antibiotics for 50 
respiratory infections. 51 
Results: 1302 participants were randomly assigned to control (n=650) or 52 
intervention (n=652). There was no significant difference in the primary outcome 53 
measure with 177/638 (27.7%) receiving antibiotics in the intervention group 54 
compared to 170/632 (26.9%) controls (OR 1.04, 95% CI 0.82, 1.34). Uptake of 55 
probiotics was low, but outcomes were similar in those who accessed probiotics 56 
(aOR 1.08, 95% CI 0.69, 1.69, compared to controls). We also found no evidence of 57 
an effect on respiratory infections or asthma exacerbations. 58 
Conclusions: In this pragmatic community-based trial in people with asthma, we 59 
found no evidence that advising use of winter probiotics reduces antibiotic 60 
prescribing. 61 
Trial Registration: ISRCTN 61742917 62 
 63 
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INTRODUCTION 78 
Acute respiratory infection is the commonest reason for attending primary care 79 
appointments and accounts for 80% of antibiotic prescriptions [2]. A Cochrane 80 
review in 2011 found that, in randomized controlled trials (RCTs) of specific patient 81 
populations, probiotic prophylaxis significantly reduces both upper respiratory tract 82 
infections (URTIs), and antibiotic prescribing rates for these infections [1]. We 83 
wanted to determine whether giving advice to take regular probiotics is an effective 84 
strategy for reducing antibiotic prescribing rates for respiratory infections in people 85 
with asthma, most of whom are older than the predominantly young child populations 86 
analyzed in the Cochrane review. People with asthma are especially vulnerable to 87 
viral URTIs, which are the commonest trigger of acute asthma exacerbations [3] and 88 
contribute substantially to the burden of unnecessary antibiotic prescriptions. Only 89 
one previous pilot study assessed effects of probiotics (combined with acupuncture) 90 
on respiratory infection rates in people with asthma. In this trial, reduced infection 91 
rates were found with the intervention, but the study was underpowered (n=17) and 92 
the findings were not statistically significant (P=0.18) [4]. Probiotics alone for 93 
preventing antibiotic use in asthmatics have not, to our knowledge, been evaluated 94 
in a prospective controlled trial [4-7].  95 
 96 
We undertook a pragmatic trial to assess whether advice to take probiotic treatment, 97 
implemented as part of routine winter infection advice, could reduce antibiotic 98 
prescription rates and respiratory infections in older children and adults with asthma 99 
in a primary care setting.  100 
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METHODS 101 
Study Design 102 
This was a parallel-group prospective RCT of a pragmatic community-based 103 
intervention – advice leaflets including recommendations to take a probiotic 104 
supplement daily through the winter months – for reducing antibiotic prescription in 105 
participants with asthma. Trial registry number ISRCTN 61742917. 106 
 107 
Participants 108 
All participants were registered patients at Ashfields Primary Care Centre, a semi-109 
urban practice in the UK caring for 23,000 patients with a nationally representative 110 
socioeconomic and racial mix. Inclusion criteria were ≥5 years (due to unreliability of 111 
asthma diagnosis in preschool children); a current diagnosis of asthma [8]; random 112 
selection of one person per household only. All patients in the practice population 113 
registered with a current diagnosis of asthma and fulfilling the inclusion criteria were 114 
enrolled in the study. 115 
 116 
Ethics and Consent 117 
The study was approved by London-Bloomsbury Research Ethics Committee 118 
(reference 13/LO/0783). Informed consent was not obtained from study participants 119 
although they were given the option to request that their data were not included in 120 
study analyses. 121 
 122 
Randomization, treatment allocation and blinding 123 
Where there was more than one eligible participant per household, the participant 124 
was randomly selected. For included participants, the randomization sequence was 125 
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computer-generated with 1:1 intervention/control ratio in random block sizes of 4, 6 126 
and 8, stratified by age (5 to 18, 19 to 34, 35 to 59, and ≥60 years). Clinical staff and 127 
the outcome assessor were blind to treatment allocation until all study data had been 128 
entered, cleaned, and locked in the study database to be sent to the study 129 
statistician. 130 
 131 
Study intervention 132 
In the UK, all patients with asthma are invited to receive annual influenza 133 
vaccination. In this study participants were sent information leaflets (see Appendix 1) 134 
over a two week period in late September 2013 together with their routine invitation 135 
for annual influenza vaccination. Participants randomized to the control group 136 
received a leaflet with standard advice about measures that have been reported to 137 
help reduce infections or asthma exacerbations [9-15]. Participants randomized to 138 
the intervention group received an information leaflet with an additional section 139 
recommending taking one Lab4 probiotic capsule (Cultech) daily from October to the 140 
end of March. In addition, the intervention group received three tokens with which 141 
they could request supplies 2 months at a time from the manufacturer via telephone 142 
or internet, which are the methods by which Lab4 is currently sold. Lab4 is a 143 
patented blend of four probiotic bacteria comprising two strains of Lactobacillus 144 
acidophilus CUL60 (NCIMB 30157) and CUL21 (NCIMB 30156), Bifidobacterium 145 
bifidum CUL20 (NCIMB 30153) and Bifidobacterium animalis (var. lactis) CUL34 146 
(NCIMB 30172) at a total 2.5 x 1010 colony forming units per capsule.  147 
 148 
Outcome measures 149 
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All outcome measures were pre-specified in the statistical analysis plan, which was 150 
finalised prior to database lock. The primary outcome measure was the proportion of 151 
participants who, within the six-month period for which probiotics were 152 
recommended, were prescribed at least one new course of one of the following 153 
antibiotics locally used for respiratory infections: amoxicillin, azithromycin, cefaclor, 154 
cefalexin, ciprofloxacin, clarithromycin, co-amoxiclav, doxycycline, erythromycin, 155 
phenoxymethylpenicillin. Secondary outcomes were based on consultations for 156 
URTIs, lower respiratory tract infections (LRTIs), asthma exacerbation or any 157 
respiratory infection, and the number and cost of antibiotic courses prescribed during 158 
the six-month intervention period. Full outcome measures along with methods used 159 
to define different forms of respiratory infection, asthma exacerbations and new 160 
episodes of illness are described in Appendix 2. 161 
 162 
Outcome data were extracted from participants’ medical records for the six-month 163 
period when probiotic consumption was recommended, 1st October 2013 to 31st 164 
March 2014, by a single investigator blind to treatment allocation. 165 
 166 
Statistical analysis 167 
In the study primary care practice, 28.4% of all patients with a current asthma 168 
diagnosis had received ≥1 of the specified antibiotics during the winter prior to this 169 
study (October 2012 to March 2013). The Cochrane systematic review found 170 
probiotics are associated with reduced antibiotic prescribing for acute URTI 171 
compared with placebo (RR 0.67, 95% CI 0.45, 0.98) [1]. For 80% power to detect a 172 
smaller effect size (RR 0.77) in this pragmatic study, with anticipated 20% loss of 173 
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outcome data and a 5% contamination rate in the control group, we planned to 174 
randomize 1258 participants. 175 
 176 
Intention to treat (ITT) analysis included all participants with data available for the 177 
relevant outcome, in the groups to which they were originally assigned, whether or 178 
not they took the intervention. Per protocol (PP) analyses were used to compare two 179 
subgroups – participants who ordered probiotics ≥1 or ≥2 times – with the control 180 
group. Adjusted analyses used logistic regression for binary outcomes, linear 181 
regression for continuous outcome variables and t-tests for cost data with boot 182 
strapping to provide robust confidence intervals on these estimates. Variables 183 
adjusted for were age group, sex, asthma severity (determinedas per Appendix 3) 184 
and numbers of courses of any antibiotics prescribed in the 12 months before entry 185 
into the trial. Sensitivity analyses further adjusted for receiving influenza vaccine 186 
during the trial. Multiple comparisons were assessed using Hochberg’s procedure to 187 
control for false discovery [16]. 188 
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RESULTS 189 
Recruitment and flow of participants is shown in Figure 1. Losses to follow-up were 190 
low – 14 (2.1%) participants in the intervention group; 18 (2.8%) in the control group. 191 
Primary analyses included the remaining 1270 participants (638 intervention; 632 192 
control), with the 2 fatalities also included in adverse events analysis. The 193 
recommended probiotic was accessed by 121 (19.0%) participants in the 194 
intervention group at least once (≥2 months’ supply), and 86 (13.5%) at least twice 195 
(≥4 months). Blinding and contamination is discussed in Appendix 4. 196 
 197 
Outcome of randomization 198 
Table 1 shows the baseline characteristics of both randomization groups with few 199 
significant differences between randomized groups. The participants who accessed 200 
probiotics in the intervention group – used for PP analyses – show some differences 201 
from the control group. They were generally older and diagnosed with asthma later in 202 
life, and more likely to have had an asthma review and influenza vaccine in the last 203 
12 months. There was no significant difference between groups in the proportion 204 
prescribed antibiotics in the last 12 months, or in other chronic disease rates, when 205 
adjusted for age and sex.  206 
 207 
Effect of the study intervention on antibiotic use 208 
Table 2 shows the study outcomes relating to antibiotic use, for the ITT and PP 209 
analyses. We found no evidence for difference between treatment groups in our 210 
primary outcome measure, prescription of a specified antibiotic during the study 211 
period, in ITT (OR 1.04, 95% CI 0.82, 1.34); or PP analyses – ≥1 probiotic token 212 
used (aOR 1.08, 95% CI 0.69, 1.69), ≥2 probiotic tokens (aOR 1.04, 95% CI 0.62, 213 
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1.75; Figure 2). We also found no evidence for a difference in secondary outcomes: 214 
use of any antibiotic, any antibiotic given for URTI/any respiratory illness, number of 215 
antibiotic courses or total cost of antibiotics – in unadjusted or adjusted analyses. We 216 
found weak evidence for a higher mean number of respiratory episodes for which 217 
antibiotics were given in the intervention (ITT) group compared to the control group 218 
(i.e. a detrimental effect), but when adjusted for multiple testing this was not found to 219 
be significant [16]. For the 10 separate antibiotic outcomes evaluated the threshold is 220 
P=0.005, using the false discovery method of Hochberg. 221 
 222 
Effect of the study intervention on respiratory health 223 
Table 3 shows outcomes related to respiratory health, for the ITT and PP analyses. 224 
We found no evidence for difference between treatment groups in respiratory 225 
outcomes: any URTI, any asthma exacerbation, any respiratory infection or total 226 
episodes of each of these categories in ITT or PP analyses, using unadjusted or 227 
adjusted analyses. We found weak evidence for detrimental effects in the 228 
intervention group in the number of people with an LRTI and mean number of LRTIs 229 
per person, but these were not significant when adjusted for multiple testing 230 
(threshold for respiratory outcomes P=0.0125) [16]. 231 
 232 
Adverse effects of the intervention 233 
There was no significant difference in serious adverse events (SAEs) between 234 
treatment groups (Table 4) when corrected for multiple testing [16]. This is further 235 
discussed in Appendix 5..  236 
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DISCUSSION 237 
In this pragmatic RCT of a recommendation for adults and older children with asthma 238 
to take daily probiotics over a single winter, we found no evidence that the 239 
intervention of advice leaflets recommending probiotic supplementation, with free 240 
access to such supplements, can reduce antibiotic prescriptions or promote 241 
improved respiratory health. Although only around 20% of these participants followed 242 
the intervention leaflet advice and took probiotics (PP groups), we found no evidence 243 
that probiotics influenced study outcomes in the PP groups. It is possible that those 244 
who accessed the probiotic would have had more respiratory infections and resulting 245 
antibiotics without the probiotic but adjustment for likely confounding factors failed to 246 
show any evidence to support this (see also Appendix 6). These results differ from 247 
previous findings in controlled trials mainly involving younger children that probiotics 248 
reduce respiratory infections and resulting antibiotic prescription rates, and cast 249 
doubt on the reproducibility of those findings in older children and adults with asthma 250 
using information leaflets. Our data suggest that real world use of probiotics to 251 
prevent winter infections and reduce antibiotic use, cannot yet be recommended 252 
despite positive findings in a Cochrane review – at least not in older children and 253 
adults with asthma. Winter infections are not necessarily all captured, since we only 254 
analyse those reported to the doctor. However, there is little reason to believe that 255 
there would be differential reporting of infections between treatment arms. Antibiotic 256 
prescriptions are generally captured, since they would appear in GP records, so this 257 
more important outcome is collected robustly. 258 
 259 
The 2011 Cochrane systematic review found participants treated with probiotics had 260 
a reduced risk of  antibiotic use for acute URTIs (RR 0.67 95% CI 0.45, 0.98) and for 261 
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≥1 URTI (OR 0.55 95% CI 0.35, 0.86) [1]. Our data challenge this finding – our 95% 262 
CI do not overlap with the point estimate of the OR/RRs of the Cochrane review. 263 
Differences between our study and those in the Cochrane review include the age 264 
group studied, our focus on people with asthma, the probiotic strain(s) used and our 265 
pragmatic trial design – the use of information leaflets and the offer of free probiotics.  266 
 267 
The developing immune system at younger ages may be more sensitive to 268 
immunological changes in the gastrointestinal tract triggered by taking probiotics [17] 269 
and 95% of subjects included in the Cochrane review were under 8 years old 270 
compared to only 3% in our study. Three recent RCTs published subsequent to the 271 
Cochrane review, found positive effects of probiotics in pediatric populations when 272 
used to prevent respiratory infections [18-20]. The studies in the Cochrane review [1] 273 
also included very few people with asthma and it is possible that the 274 
immunopathology of asthma leads to differential response to probiotics [21,22]. One 275 
small pilot study suggested probiotics may have positive effects in asthma, although 276 
the findings were inconclusive due to low statistical power [4].  277 
 278 
All three studies included in the meta-analysis on antibiotic prescribing in the 279 
Cochrane review, and all four studies in another meta-analysis showing similar 280 
evidence for a benefit, evaluated Lactobacillus rhamnosus GG, in some instances in 281 
conjunction with a second probiotic, Bifidobacterium lactis Bb-12 [23]. Immune 282 
effects of probiotics may be species- or strain- rather than genus-specific [24,25]. It 283 
is also possible that publication bias, which is difficult to assess in meta-analyses of 284 
small numbers of studies, or time-lag bias may have contributed to the Cochrane 285 
review’s findings [26]. We identified a data-entry error in the 2011 Cochrane review, 286 
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and an issue of differential loss to follow-up – an assumption that the 18.3% in the 287 
probiotic group and 4.6% in the control group who were lost to follow-up would all 288 
have had no URTIs – both relating to the included studies of Cobo Sanz et al. (See 289 
Appendix 7) [1,27]. Together with our negative trial findings, these issues support a 290 
need to update the Cochrane systematic review of probiotics for URTI. – 291 
 292 
One final explanation for the difference between our findings and those of previous 293 
studies may be the use of intact probiotic capsules or tablets rather than a liquid 294 
formulation. Only one of two RCTs in the Cochrane review using a non-liquid 295 
probiotic formulation for prevention of respiratory infections showed a benefit in 296 
reducing URTIs [28,29]. Since then, one other RCT showed reduced symptoms of 297 
URTIs using probiotic  capsules [20], although it is unclear whether the young 298 
participants dissolved the capsules’ powder contents in  liquid as other pediatric 299 
studies have done [30]. If probiotics prevent URTI through local effects on the upper 300 
respiratory mucosa, then direct contact between probiotic and mucosa may be 301 
important for efficacy. 302 
 303 
There is a need for new ways to prevent URTI and reduce antibiotic prescribing in 304 
asthmatics and non-asthmatics that are cost-effective, safe and acceptable to 305 
patients. In a population of people with asthma, we found that probiotics were not 306 
effective in preventing antibiotic prescription, in contrast to the findings of the 307 
Cochrane review. We also found no effect on URTI, LRTI or asthma exacerbation 308 
rates. Our data suggest that probiotics may not be effective for prophylaxis against 309 
URTIs, and cast doubt on the reproducibility of earlier positive trials. Therefore, there 310 
is not currently enough evidence to recommend their use for preventing infections 311 
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and antibiotic use in at risk populations such as asthmatics. Further work is needed 312 
to evaluate whether specific probiotic formulations modulate systemic immune 313 
reponses or mucosal defences, before developing new interventions to reduce the 314 
burden of respiratory infection.  315 
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 316 TABLE 1 Baseline characteristics of study participants 
 
Randomized 
control group 
Randomized 
intervention 
group 
Obtaining any 
probiotic 
package 
Obtaining 2-3 
probiotic 
packages 
 
(n=650) (n=652) (n=123) (n=88) 
Age group: 
         5-18 years 80  (12) 80  (12) 10  (8) 7  (8) 
     19-34 years 95  (15) 101  (15) 7  (6) 2  (2) 
     35-59 years 254  (39) 251  (38) 34  (28) 21  (24) 
     60 years and over 221  (34) 220  (34) 72  (59) 58  (66) 
Age:  48  (32, 66) 49  (32, 65) 64***  (46, 70) 65***  (54, 74) 
Male 277  (43) 316*  (49) 52  (42) 42  (48) 
Body mass index:  26.8  
(23.5, 30.7) 
27.2  
(24.2, 30.7) 
28.2 
(25.0, 31.2) 
27.4  
(24.9, 30.9) 
Age diagnosed asthma:  31  (11, 52) 33  (11, 50) 46***  (30, 59) 47***  (31, 61) 
Ethnic Group: 
         White 577  (89) 595  (91) 109  (89) 82  (93) 
     Black 2  (0.3) 1  (0.2) 0  (0) 0  (0) 
     Asian 4  (0.6) 1  (0.2) 0  (0) 0  (0) 
     Mixed 45  (7) 39  (6) 12  (10) 6  (7) 
     Not Specified 22  (3) 16  (3) 2  (2) 0  (0) 
Smoking status: 
         Never smoked 385  (60) 368 (57) 76  (62) 54  (61) 
     Ex smoker 188  (29) 200  (31) 37  (30) 29  (33) 
     Current smoker 66  (10) 67  (10) 7  (6) 3  (3) 
     Not specified 11  (2) 17  (3) 3  (2) 2  (2) 
Asthma Severity: 
         Step 1 103  (16) 116  (18) 15  (12) 7  (8) 
     Step 2 or 3 283  (44) 272  (42) 51  (42) 41  (47) 
     Step 3 or 4 202  (31) 207  (32) 40  (33) 27  (31) 
     Step 5 62  (9) 57  (9) 16  (13) 13  (15) 
Other disease registers: 
     Diabetes mellitus 56  (9) 37*  (6) 5  (4) 4  (5) 
     Coronary heart disease 36  (6) 32  (5) 10  (8) 9  (10) 
     Stoke or TIA 11  (2) 17  (3) 2  (2) 1  (1) 
     COPD 43  (7) 46  (7) 9  (7) 8  (9) 
     Cancer 31  (5) 37  (6) 13* (11) 9*  (10) 
     Rheumatoid arthritis 5  (0.8) 4  (0.6) 1  (0.8) 1  (1) 
In last 12 months: 
     Any antibiotics 330  (51) 327  (50) 71  (58) 55*  (63) 
     Oral corticosteroids 132  (20) 123  (19) 26  (21) 21  (24) 
     Asthma review 377  (58) 373  (57) 86*  (70) 64**  (73) 
     Influenza vaccine 416  (64) 409  (63) 98***  (80) 72***  (82) 
Comparisons are made between randomized groups and for those within the intervention 
group who obtained probiotic packages at least once, and two to three times. Data are 
number (percent) or median (25th, 75th centile). TIA: transient ischemic attack; COPD: 
chronic obstructive pulmonary disease. *p<0.05, **p<0.01 and ***p<0.001 comparing 
intervention group or PP groups obtaining probiotics to the control group (unadjusted 
analysis). No other such comparisons were significant.  
 
17 
 
 
TABLE 2 Effects of advice to take probiotics on antibiotic prescribing outcomes 
  
Randomized 
control group 
Randomized 
intervention 
group† 
Obtaining any 
probiotic 
package‡ 
Obtaining 2-3 
probiotic 
packages‡ 
Randomized 
intervention 
group† 
Obtaining 
any probiotic 
package‡ 
Obtaining 2-3 
probiotic 
packages‡ 
 
(n=632) (n=638) (n=121) (n=86) 
   
  Number (percent) for the following outcomes:   
Odds Ratios (95% CI) for specified group 
compared to randomized control group: 
Taken any selected 
antibiotic 
170  (26.9) 177  (27.7) 38  (31.4) 28  (32.6) 
1.04 
(0.82, 1.34) 
1.08 
(0.69, 1.69) 
1.04 
(0.62, 1.75) 
Taken any antibiotic 212  (33.5) 216  (33.9) 46  (38) 32  (37.2) 
1.01 
(0.80, 1.28) 
1.09 
(0.71, 1.68) 
0.97 
(0.58, 1.6) 
Had URTI without wheeze, 
treated by antibiotics 27  (4.3) 30  (4.7) 5  (4.1) 4  (4.7) 
1.11 
(0.65, 1.88) 
1.15 
(0.42, 3.12) 
1.54 
(0.5, 4.72) 
Had respiratory episode, 
treated by antibiotics 
129  (20.4) 143  (22.4) 31  (25.6) 24  (27.9) 
1.13 
(0.86, 1.47) 
1.16 
(0.72, 1.87) 
1.2 
(0.7, 2.06) 
 
Mean (percentage with one, percentage with two or more):                                                                                                      
Incidence Rate Ratio (95% CI) for specified 
group compared to randomized control group: 
Number of selected 
antibiotic courses 
0.42                                                                                              
(17.4, 9.5) 
0.47                                
(16.3, 11.4) 
0.50
(9.8, 11.6) 
0.51                                                           
(19.8, 12.8) 
1.11
(0.88, 1.38) 
1.02
(0.71, 1.46) 
0.97 
(0.64, 1.46) 
Number of any antibiotic 
courses 
0.59                                                                                                 
(19.6, 13.9) 
0.61                             
(19.0, 14.9) 
0.64                               
(24.0, 14.0) 
0.63
(20.9, 16.3) 
1.03
(0.84, 1.26) 
0.95 
(0.69, 1.32) 
0.88 
(0.6, 1.29) 
No. URTIs without wheeze 
given antibiotics 
0.04                                                                                                
(4.1, 0.2) 
0.05                              
(4.1, 0.6) 
0.04                               
(4.1, 0) 
0.05                                                           
(4.7, 0) 
1.24
(0.72, 2.12) 
1.08
(0.41, 2.83) 
1.36 
(0.47, 3.99) 
Combined all respiratory 
episodes given antibiotics 
0.23                                                                                                 
(18.2, 2.2) 
0.30*                                                   
(16.1, 6.3) 
0.32                              
(19.0, 6.6) 
0.35                                                                                      
(20.9, 7.0) 
1.31
(1.03, 1.66) 
1.24
(0.87, 1.78) 
1.26 
(0.84, 1.88) 
 
Mean (standard deviation): 
Difference in cost for specified group from 
randomized control group (boot-strapped 95% 
CI): 
Total cost per person of 
selected antibiotics (£) 
1.49 
(SD=10.9) 
1.75 
(SD=16.58) 
4.41 
(SD=37.18) 
5.74 
(SD=44.08) 
£0.25 
(-1.29, 1.79) 
£2.33 
(-3.80, 8.46) 
£3.50 
(-5.26, 12.27) 
Total cost per person of all 
antibiotics (£) 
2.41 
(SD=11.68) 
2.38 
(SD=16.96) 
4.74 
(SD=37.18) 
5.98 
(SD=44.07) 
£-0.04 
(-1.62, 1.54) 
£1.74 
(-3.84, 8.51) 
£2.81 
(-5.14, 12.15) 
Comparison is made between randomized groups comparing the intervention group to the control group, and between the PP groups of 
participants following additional advice and obtaining probiotics during the study, comparing them to the randomized control group. 
†From unadjusted analyses. ‡From analyses adjusted for age group, sex, asthma severity and use of any antibiotics in 12 months prior 
to study. *p<0.05 compared to control group.  
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TABLE 3 Effects of advice to take probiotics on respiratory outcomes not related to antibiotic prescriptions  
  
Randomized 
control group 
Randomized 
interention 
group† 
Obtaining any 
probiotic 
package‡ 
Obtaining 2-3 
probiotic 
packages‡ 
Randomized 
intervention 
group† 
Obtaining 
any probiotic 
package‡ 
Obtaining 2-3 
probiotic 
packages‡ 
 
(n=632) (n=638) (n=121) (n=86) 
   
  Number (percent) for the following outcomes:   
Odds Ratios (95% CI) for specified group 
compared to randomized control group: 
Had any URTI without 
wheeze 
43  (6.8) 48  (7.5) 11  (9.1) 7  (8.1) 
1.11 
(0.73, 1.71) 
1.56 
(0.76, 3.20) 
1.5 
(0.63, 3.59) 
Had any LRTI without 
wheeze 
63  (10.0) 87* (13.6) 17  (14.0) 11  (12.8) 
1.43 
(1.01,2.01) 
1.29 
(0.71, 2.33) 
1.07 
(0.53, 2.18) 
Had any asthma 
exacerbations/wheeze 
85  (13.4) 84  (13.2) 19  (15.7) 15  (17.4) 
0.98 
(0.71, 1.35) 
1.12 
(0.64, 1.99) 
1.17 
(0.61, 2.23) 
Had any respiratory 
infection 
177  (28.0) 188  (29.5) 40  (33.1) 29  (33.7) 
1.07 
(0.84, 1.37) 
1.19 
(0.77, 1.84) 
1.16 
(0.70, 1.93) 
Received influenza 
vaccine during trial 
430  (68.0) 454  (71.2) 111*** (91.7) 78** (90.7) 
1.16 
(0.91, 1.47) 
4.34 
(2.12, 8.91) 
2.95 
(1.31, 6.65) 
Received asthma review 
during trial 
221  (35.0) 207  (32.4) 47  (38.8) 36  (41.9) 
0.89 
(0.71, 1.13) 
0.94 
(0.62, 1.43) 
1.01 
(0.62, 1.63) 
 
Mean (percentage with one, percentage with two or more): 
Incidence Rate Ratio (95% CI) for specified group 
compared to randomized control group: 
Number of URTIs without 
wheeze 
0.08                                                                                                 
(5.4, 1.4) 
0.09                             
(6.6, 0.9) 
0.09                               
(9.1, 0) 
0.08                            
(8.1, 0) 
1.03
(0.67, 1.58) 
1.15 
(0.55, 2.42) 
1.06  
(0.43, 2.62) 
Number of LRTIs without 
wheeze 
0.12                                                                                                 
(8.5, 1.4) 
0.17*                              
(10.8, 2.8) 
0.17                              
(10.7, 3.3) 
0.15                                                          
(10.5, 2.3) 
1.47
(1.05, 2.04) 
1.34 
(0.78, 2.32) 
1.12  
(0.58, 2.16) 
Number of asthma 
exacerbations/wheeze 
0.17                                                                                                 
(11.1, 2.4) 
0.16                             
(10.5, 2.7) 
0.18                               
(13.2, 2.5) 
0.21                            
(14.0, 3.5) 
0.95
(0.70, 1.31) 
1.00 
(0.59, 1.68) 
1.03  
(0.58, 1.84) 
Total number of all 
Respiratory episodes 
0.37                                                                                                
(21.4, 6.6) 
0.42                              
(20.5, 8.9) 
0.45                               
(24.0, 9.1) 
0.44                            
(24.4, 9.3) 
1.13
(0.92, 1.38) 
1.17 
(0.84, 1.62) 
1.09  
(0.75, 1.59) 
Comparison is made between randomized groups comparing the intervention group to the control group, and between the PP groups of 
participants following additional advice and obtaining probiotics during the study, to the randomized control group. †From unadjusted 
analyses. ‡From analyses adjusted for age group, sex, asthma severity and use of any antibiotics in 12 months prior to study. *p<0.05 
compared to control group, **p<0.01 compared to control group, ***p<0.001 compared to control group.  
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TABLE 4 Serious adverse events 
Type of serious 
adverse event 
Randomized 
control group 
Randomized 
intervention group 
Obtaining any 
probiotic package 
Obtaining 2-3 
probiotic packages 
(n=632) (n=640) (n=122) (n=87) 
  Counts, Percentages (95% CI percentages) for the following SAEs: 
  
Respiratory  10                                                                                                          
1.6 (0.8-2.9) 
6                                          
0.9 (0.3-2.0) 
1                                                                         
0.8 (0.02-4.5) 
1                                                                             
1.1 (0.03-6.2) 
Gastrointestinal 6                                                                                                                  
0.9 (0.3-2.1) 
10                                      
1.6 (0.8-2.9) 
0                                                                             
0 (0-3.0) 
0                                                                         
0 (0-4.2) 
Infection 
(excluding above) 
2                                                                                                                  
0.3 (0.04-1.1) 
4                                    
0.6 (0.2-1.6) 
2                                                                               
1.6 (0.2-5.8) 
1                                                                       
1.1 (0.03-6.2) 
Other  20                                                                                                                  
3.2 (1.9-4.8) 
31                                    
4.8 (3.3-6.8) 
10*                                     
8.2 (4.0-14.6) 
6                                                                                           
6.9 (2.6-14.4) 
This table compares each category of SAE according to the randomized groups and the PP groups of 
those receiving additional advice who obtained probiotics, counting number of participants affected by each 
category of SAE. *p<0.05 compared to control group, adjusted for age and sex. 
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Figure Legends 
 
FIGURE 1 CONSORT flow diagram showing participant recruitment and flow 
through the study. 
* PP1 is ≥1 set of probiotics ordered; PP2 is ≥2 sets of probiotics ordered. Each set 
included sufficient probiotics for 2 months. 
 
FIGURE 2 Summarised effect size for the study primary outcome.  
Data represent the OR (95% CI) for ≥1 antibiotic prescription during the 6-month 
intervention period, in the intervention compared with control group. OR is 
unadjusted for the intention to treat (ITT) analysis, and adjusted for age group, sex, 
asthma severity and use of any antibiotics in the 12 months prior to the study for per 
protocol (PP) analyses.  
* PP1 is ≥1 set of probiotics ordered; PP2 is ≥2 sets of probiotics ordered. Each set 
included sufficient probiotics for 2 months. 
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Appendix 1: Study intervention development 
Information on the standard information leaflet sent to the control group was gleaned 
from a number of sources including information leaflets aimed at members of the 
public, information leaflets directed at health professionals and professional papers 
[9-15]. This included advice on receiving influenza vaccination, covering the mouth 
when coughing, hand hygiene, and having an asthma inhaler check. The intervention 
and control group information leaflets were developed by 3 authors (TDHS, RJB, JC) 
with input from the trial site research team until it was felt that all the information – 
both the standard advice and advice about probiotics – would be understood by most 
people with asthma. Both information leaflets consisted of 2 pages sent on a single 
sheet of double-sided A4 paper. 
 
The control leaflet is shown above and the intervention leaflet below. 
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While there is good evidence that leaflets can be used in a productive way during a 
face-to-face consultation, for example in reinforcing information about progression of 
common infections which do not need antibiotics [31], it is less clear whether postal 
leaflets used without any personal contact can be similarly effective in influencing 
action of patients. However, the potential benefit of probiotics in reducing infection 
rates is thought to be in terms of prevention rather than cure [1] so it was not 
practical to recruit all eligible patients attending a face-to-face consultation. 
 
As this study involved all patients with asthma within the surgery (with the exception 
of under 5s and those living in the same household as others involved) it was not 
practical to pilot the study leaflets locally without unblinding future participants or 
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preventing those in the pilot study from taking part. There was no evidence from the 
instances where participants discussed probiotics with the clinical staff, the trial team 
or the supplier Cultech that the information leaflets were misunderstood with the only 
recurring aspect that seemed to confuse participants was why the probiotic capsules 
would be provided for free. It is unclear whether this put any participants off applying 
for probiotics who would otherwise have wished to take them.  
 
A further offer with a repeated leaflet may have been useful but in order to fit in with 
the pragmatic nature of the trial, it was felt that it was better only to contact 
participants with a leaflet at a time when they would usually have received 
correspondence from the surgery anyway (their annual invite letter for an influenza 
vaccination). Furthermore, this study aimed to see whether a low cost intervention – 
including an extra leaflet in post that would have been sent anyway – was effective, 
and subsequent methods of communication would have significantly increased the 
cost although probably improved uptake of the probiotic capsule.  
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Appendix 2: Full details of outcome measures 
Any deviations in outcome measures from the trial protocol are noted below. All 
outcome measures came from review of participants’ medical notes to obtain history 
of face-to-face, telephone or third party consultations and acute antibiotic 
prescriptions during the six-month trial period. Only a minority of respiratory infection 
episodes result in GP consultation [32], although it is likely that there will be a 
correlation between severity and likelihood of consulting. However, diary-keeping of 
symptoms can be confusing as symptoms of allergic rhinitis, common in people with 
asthma [33], are often indistinguishable from those of upper respiratory tract 
infections (URTIs) [34].  
 
Primary outcome measure 
The primary endpoint was the percentage of participants who within the six month 
period for which probiotics were recommended, were prescribed at least one acute 
course of one of the following antibiotics: 
 Amoxicillin 
 Azithromycin 
 Cefaclor 
 Cefalexin 
 Ciprofloxacin 
 Clarithromycin 
 Co-amoxiclav 
 Doxycycline 
 Erythromycin 
 Phenoxymethylpenicillin 
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These were selected based on guidelines from the local health authority for 
treatment of respiratory infections, and are not recommended in local guidelines 
as first-line treatment for other common infections such as cellulitis or urinary 
tract infections.  
 
Secondary outcome measures 
1. Mean number of antibiotic prescriptions for any of the above antibiotics per 
participant. This is another way of measuring effects on antibiotic prescribing. 
The following eight secondary outcome measures looked at antibiotic prescribing 
more generally: 
2. Total cost of all antibiotic prescriptions listed above during the six-month study 
period per participant. This was based on the NHS drug tariff for England and 
Wales at the time the prescription was issued. This was a minor change in how 
antibiotics are costed compared to that planned in the study protocol, since 
these more accurate data were available. The protocol mentioned cost of 
antibiotics as a single outcome measure but did not specify whether this was to 
be the ones selected for use in respiratory infections or all antibiotics, which 
have therefore been separately reported as two secondary outcome measures 
(this one and outcome 5). 
3. Percentage of study group prescribed at least one course of any type of oral 
antibiotics. 
4. Mean number of any type of oral antibiotic prescriptions per participant during 
the six months. 
5. Total cost of all types of oral antibiotic prescriptions per participant (determined 
as per 2).  
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6. Percentage of group having at least one new URTI episode for which antibiotics 
were prescribed. Of note, this outcome measure and the following 3 secondary 
outcome measures were included in the statistical analysis plan after clinical trial 
registration, and are therefore post-hoc analyses. They were added because the 
information was available from the practice electronic records, and were 
considered to be relevant additional measures of antibiotic use for specific 
respiratory indications. 
7. Mean number of new URTI episodes for which antibiotics were issued per 
participant. 
8. Percentage of group having at least one respiratory episode for which antibiotics 
were prescribed. 
9. Mean number of all respiratory episodes for which antibiotics were issued per 
participant. 
People were considered to be suffering from URTIs if they fulfilled the criteria in 
the flow chart shown below [1,35,36]. A new URTI episode was defined as one 
where there was at least one day completely free of symptoms since the 
previous respiratory episode, in line with two studies included in the Cochrane 
review [1,37,38]. Where this information was not available, it was assumed that 
any infection presenting four weeks or more after the earliest known date of 
symptoms of a previous respiratory episode was a new infection. This allows a 
week longer for recovery than the mean length for acute bronchitis according to 
the NICE guidelines “Respiratory tract infections – antibiotic prescribing” [39].  
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Flow chart to determine participants diagnosed with URTIs according to standard 
definitions [1,35,36]. To stop duplication of respiratory episodes, URTIs that were not 
recorded as resolving and were within 4 weeks of onset were not included if they 
developed into LRTI or asthma exacerbation during this time. 
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Any antibiotic prescribed during a consultation when someone was seen for a 
respiratory episode was considered to be prescribed for the respiratory illness 
unless an alternative reason was recorded. If there was no reason recorded on 
the day of issue but a respiratory infection was assumed to be ongoing 
according to the definition in the previous paragraph, any of the ten antibiotics 
listed in the primary outcome measure were assumed to be for the respiratory 
illness, whereas alternative antibiotics were not. 
The following eight secondary outcome measures looked at the effects of probiotics 
on respiratory infection rates more generally: 
10. Percentage of participants who consulted at least once for URTI during the six-
month study period. 
11. Mean number of URTI episodes per participant during the six months. 
12. Percentage of participants who consulted at least once for lower respiratory tract 
infection (LRTI) during this six-month period.  
13. Mean number of LRTI episodes per participant during the six-month study 
period. 
14. Percentage of participants consulting at least once for an acute exacerbation of 
asthma during the six months. This outcome and outcome 15 were added to the 
statistical analysis plan after registration of the trial protocol, so are post-hoc 
analyses. They were included because the information was available from the 
practice electronic records, and LRTIs are an important complication of URTIs.   
15. Mean number of acute asthma exacerbation episodes per participant during the 
six months. 
16. Percentage of participants consulting at least once with acute respiratory 
symptoms during this time. This might be due to URTI, LRTI, or an exacerbation 
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of asthma. This outcome measure and outcome 17 were added to the statistical 
analysis plan after registration of the trial protocol, so are post-hoc analyses. 
They were added because the information was available from the practice 
electronic records, and asthma exacerbations are an important complication of 
URTIs. 
17. Mean number of acute respiratory episodes for each participant. 
A participant was defined as having LRTI according to the flow chart shown 
below [35,40-43]. A new episode of LRTI was defined as per URTI episodes 
above, and if someone with URTI subsequently developed LRTI before URTI 
had resolved, only LRTI was included to stop a continuation of the same 
respiratory episode being counted twice. 
An asthma exacerbation was defined according to the documented presence of 
reported or auscultated wheeze, or auscultated expiratory rhonchus, or 
according to a documented temporary need for additional asthma treatment or 
hospitalization. A new episode of asthma exacerbation was determined 
according to the European Respiratory Society definition of a preceding period of 
at least one week on usual treatment and out of hospital [44]. In anyone in whom 
URTI or LRTI progressed into an acute asthma exacerbation without becoming 
symptom free or within four weeks of onset (as per the definition for a new 
episode), only the acute asthma exacerbation was counted to stop a 
continuation of a single respiratory episode being counted more than once.  
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Flow chart to determine participants diagnosed with LRTIs according to standard 
definitions [1,40-43]. To stop duplication of respiratory episodes, LRTIs that were not 
recorded as resolving and were within 4 weeks of onset were not included if they 
developed into an asthma exacerbation during this time. 
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Per protocol (PP) analyses were undertaken using two different datasets: 
1. Participants who used their voucher to order Lab4 probiotic capsules 
(Cultech) at least once during the six-month study period. 
2. Participants who used their voucher to order Lab4 probiotic capsules at least 
twice during the six-month study period. This was a deviation from the 
registered trial protocol, as data were not available for the protocol-defined 
group of participants who took probiotic for at least half of the trial period. 
However, ordering the probiotic for a second time was felt to be an 
appropriate surrogate measure.  
 
Outcome data were extracted from participants’ medical records for the six-month 
period when probiotic consumption was recommended, 1st October 2013 to 31st 
March 2014, by a single investigator (TDHS) blind to treatment allocation. Once the 
data had been checked by another investigator (RJB) blind to treatment allocation, 
and the database locked and statistical analysis plan approved, the locked database 
was sent to the statistician (HW) for analysis.  
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Appendix 3: Definitions used for asthma severity 
 
Definitions used for asthma severity using the 5 step chart taken from the British 
Thoracic Society (BTS) and the Scottish Intercollegiate Guidelines Network (SIGN)’s 
revised 2011 guidelines: British guideline on the management of asthma [45]. The 
orange boxes have been added to show how the measure of asthma severity used 
in this trial relates to the guidelines, when looking at prescriptions issued in the 12 
month period preceding the trial. *One course of oral corticosteroids for asthma is 
allowed during that 12 months as a rescue medication but two or more courses 
would take the participant into step 5 for the purposes of this trial. †No participant 
received any oral β2 agonist. SABA: short-acting β2 agonist; ICS: inhaled 
corticosteroids; LABA: long-acting β2 agonist; LTRA: leukotriene receptor antagonist; 
OCS: oral corticosteroids.  
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Appendix 4: Blinding and contamination 
 
While participants were not blinded to treatment allocation, every attempt was made 
to keep clinical staff and statistical analyzers blinded as to allocation of the two 
different information leaflets. One of the authors of this study (TDHS) worked at 
Ashfields Primary Care Centre throughout the trial period at 0.75 full-time equivalent 
hours. In the course of his clinical work, he became unblinded on just one occasion 
when a participant disclosed he was taking probiotic in the course of an otherwise 
normal consultation. Two other GPs surveyed who were not part of the trial team 
reported one and two participants respectively who had asked whether or not they 
should take the probiotics recommended in the leaflet or otherwise disclosed that 
they were already taking them. No other unblinding events were reported.  
 
TDHS also became intentionally unblinded acting as an investigator in eight other 
cases due to queries from clinical colleagues about other participants’ suitability to 
take probiotics, and from Cultech due to queries about applicants for free Lab4 
probiotics. The outcome assessor (TDHS) was otherwise blinded until after the data 
collection had been entered, cleaned and locked. 
 
It is difficult to state the actual contamination rate in the study but we can assume it 
was low. Only one person per household was randomized as two people receiving 
different leaflets would obviously unblind participants to the other branch of the study 
(see inclusion criteria). In accordance with advice from the Research Ethics 
Committee, participants were not actively aware that there was more than one 
version of the information leaflet. However, participants were informed on both the 
control and intervention advice leaflets (see Figures S1 and S2) that the 
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effectiveness of the leaflets was being studied by the research team and given ways 
to contact the research team if they had any queries. Only five participants contacted 
the research team but in each case it was to discuss whether to start the probiotic or 
not rather than to query any of the additional information on either leaflet. No one 
contacted the research team or Cultech Ltd. to protest that they had heard there was 
another leaflet or to request that they received probiotics despite receiving the 
control advice leaflet. There was one case where a study participant with asthma, 
randomised to probiotic advice, contacted the surgery to request that she receive 
additional probiotics to give to her daughter who was not on the asthma register and 
she was advised that the probiotics were only being provided free for people with 
asthma. 
 
There was a low level of unblinding of the participants’ physicians as to which group 
they had been randomized to. There was a low loss of outcome data and 
contamination rates were kept low. In hindsight, 20% loss of outcome data was a 
conservative estimate for loss of outcome data. Our rationale for using such a 
conservative measure was based around the unknown. Having given participants the 
option of contacting the trial team to withdraw consent for staff to access their 
medical records to obtain the study data (in line with recommendations by the 
Research Ethics Committee), we could not find any figures for opt outs or indeed any 
previous trials taking this approach. In our trial, not one single person contacted the 
research team to withdraw consent, and so the only known participants where there 
was loss of outcome data was the 2.5% who deregistered from the surgery. This was 
presumably due to moving away from the area as Ashfields Primary Care Centre is 
43 
 
the sole supplier of primary care services to more than 95% patients living in its 
catchment area.  
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Appendix 5: Details of SAEs and losses to follow up amongst the PP groups  
 
Two participants who left the study (due to death or moving out of area) obtained 
Lab4 probiotics (Cultech). They were both in the 60 and over age group. One 
obtained three probiotic packages and moved out of area during the trial, 
deregistering with the surgery in February. The other was one of the two participants 
who died, a participant in the 60 and over group, who received two packages of 
probiotics. They were at step 5 of BTS asthma treatment (indicating severe asthma) 
[45] and were already known to have terminal adenocarcinoma of the lung before the 
trial began. The death was expected. Prior to this, they were involved in another SAE 
when they were admitted with a discomfort and shuffling gait in order to exclude 
spinal cord compression successfully. 
 
The difference in “other adverse events” became non-significant when Hochberg’s 
procedure was used to correct for multiple testing [16] and cases were 
heterogeneous with only hospital admission for chest pain occurring more than once 
(see table below). In these two cases, admission was made to exclude a different 
diagnosis in each case, with myocardial infarction and pulmonary embolism 
excluded successfully, and observation of the participants’ notes for a further five 
months showed no recurring or persisting symptoms. 
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Study 
number 
No. 
probiotic 
packages 
Category 
of SAE 
All recorded SAEs 
XY0262 1 Other Emergency Caesarean section due to failure to 
progress 
XY0281 3 Other Emergency admission for acute urinary retention 
Other Subsequent elective admission for TURP 
XY0283 3 Other Planned elective surgery for CABG (cancelled by 
hospital) 
Other Elective surgery for CABG (proceeded) 
XY0349 2 Other Admission to successfully exclude spinal cord 
compression 
Respiratory Expected death - had adenocarcinoma lung since 
before trial 
XY0407 3 Other Admission excluded PE, diagnosed with 
musculoskeletal pain 
XY0601 1 Other Diagnosed and treated for testicular torsion 
XY0728 1 Other Elective admission for anterior vaginal repair 
XY0769 1 Infection Admitted with leg cellulitis 
Other Was given alcohol detoxification on same 
admission 
XY1250 3  Other Admitted to successfully exclude MI, diagnosed 
atypical chest pain 
XY1392 3 Other Elective admission for total knee replacement 
Infection Readmitted for postoperative infection 
Only leg infections and chest pain occurred in more than one participant and these 
were thought to have different causes and so not bear any repeated relationship to 
Lab4 probiotic (Cultech). TURP – transurethral resection of the prostate, CABG – 
coronary artery bypass graft, PE – pulmonary embolism, MI – myocardial infarction.  
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Appendix 6: Accounting for differences in PP groups compared to randomized 
control group 
 
The participants who accessed probiotics in the intervention group – used for PP 
analyses – show some differences from those who did not access probiotics (not 
shown directly) and from the control group (shown in Table 1). They were generally 
older (p<0.0001) and had been given a first diagnosis in later life (p<0.0001). 
However, when age of first diagnosis was adjusted for age and sex it became non-
significant. Those obtaining probiotics were also more likely to have had an asthma 
review in the last 12 months (p=0.014), and to have received an influenza vaccine 
the previous vaccination season (p=0.0007). These differences were also largely due 
to differences in age distributions as there was a smaller significance (p=0.03 for 
asthma review and p=0.01 for influenza vaccination) when analyses adjusted for age 
and sex. Additional adjusted analysis was performed for those who received 
influenza vaccination during the study period which is likely to correlate with a history 
of previous vaccination and attending for asthma reviews [46].  
 
There was a higher proportion of participants who had been prescribed antibiotics in 
the previous 12 months amongst the PP groups. Unadjusted analysis just touched 
significance only amongst those who received 2 to 3 probiotic packages (p=0.04) but 
there was no significant difference in either group who obtained probiotics when 
analysis adjusted for age and sex. Analyses of outcome measures included 
adjustment for past antibiotic use as agreed before analysis in the statistical plan. 
 
Other differences included history of chronic diseases with some diseases more and 
some less common amongst those who requested probiotics but only those with a 
history of cancer had a significant difference (p=0.01). Again, this was non-significant 
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using analysis adjusted for age and sex and the overall numbers are small with only 
around 5% of those in the study having any history of cancer. Those requesting 
probiotics tended to have slightly more severe asthma (according to the definition 
shown in Appendix 5 [45]) than those in the control group, and although this was not 
significant in adjusted or unadjusted analyses, outcome measures were adjusted for 
this in accordance with the statistical plan.  
 
Analyses of the effects on antibiotic use and on respiratory health in the PP groups 
compared to the randomized control groups looked at adjusted and unadjusted 
analyses. Adjusted analyses as published in Tables 2 and 3, adjusted for age group, 
sex, asthma severity, and use of any antibiotics in the 12 months prior to the study. 
In measures where the P value approached significance (P<0.05), further adjustment 
was made for participants receiving influenza vaccination in the same season as the 
trial. This further adjustment made little difference to the resulting P values (see table 
below). 
 
Outcome measure Unadjusted Adjusted for age, 
sex, asthma severity 
& 12 month previous 
use of antibiotics 
Further adjusted for 
receiving flu 
vaccination during 
trial 
Combined all 
respiratory episodes 
given antibiotics* 
0.025 0.016 0.020 
Had any LRTI 
without wheeze* 
0.038 0.045 0.036 
Number of LRTIs 
without wheeze* 
0.024 0.021 0.027 
The effect of adjustments carried out as per the pre-stipulated statistical analysis 
plan on for outcome measures with significant p values (<0.05) comparing the ITT 
intervention group to the control group. When multiple comparisons were accounted 
for using the method of Benjamini and Hochberg [16], there were no significant 
findings in either PP intervention group compared to the control group using 
unadjusted or adjusted data. 
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As those in the intervention group who elected to take Lab4 probiotics (Cultech) (the 
PP groups) were more likely to have obtained antibiotics for respiratory infections the 
previous winter, they may have been more likely to otherwise obtain them during the 
study period. The baseline characteristics suggest they may have more severe 
asthma (measured by what drugs they have been prescribed) although this may also 
reflect healthcare-seeking behaviour rather than disease severity. Like many UK 
sites, both the official asthma review and the influenza vaccination recorded on 
baseline characteristics are annual events at Ashfields Primary Care Centre when 
patients with current asthma are invited to attend, regardless of the severity of their 
disease. The higher attendance rate for influenza vaccination amongst those who 
accessed probiotics suggests a difference in healthcare-seeking behaviour. 
 
In summary, those who accessed the probiotic intervention may have had more 
severe asthma, but their increased attendance for influenza vaccination suggests 
they may have different healthcare seeking behaviour compared with those who did 
not access the intervention, and this could explain their increased uptake of the 
probiotic intervention. We attempted to adjust all analyses for these possible 
differences, by including age group, sex, asthma severity and use of antibiotics in the 
past 12 months in the model; and by additionally adjusting for influenza vaccination 
during the trial period in a post-hoc analysis. This additional adjustment had no 
significant impact on the study outcomes. 
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It is not always possible to fully adjust statistically for differences in baseline 
measures in self-selecting groups, and the relatively low uptake of probiotic amongst 
those given the intervention advice leaflet meant that this study may be 
underpowered to pick up significant differences in the PP groups. However, the 
outcome data generally showed no sign of positive effects from probiotics. Of the 18 
outcome measures assessed, only three point estimates showed effect estimates in 
a beneficial direction for the randomized intervention group – number of patients 
having any asthma exacerbations/wheeze during the trial, total number of asthma 
exacerbations/wheeze and cost per person of all antibiotics regardless of whether 
they were for respiratory or non-respiratory causes. For the two PP groups, only one 
out of the 18 outcome measures showed an effect estimate in a beneficial direction – 
number of any antibiotic courses for any condition including non-respiratory as well 
as respiratory causes; and a further two outcome measures for one but not both PP 
groups – number of patients taking an antibiotic for any condition and total number of 
antibiotic courses from the specified list for respiratory conditions.  
 
An additional notable difference amongst those in the PP groups who followed the 
advice of the intervention leaflet to take probiotics, is that they had received their 
diagnosis at a significantly later age, although this probably reflects the generally 
older age group of people wishing to take the probiotic as the difference was non-
significant when adjusted for age. In older participants, the earliest known age of 
diagnosis is likely to be less reliable as UK patient records have generally only been 
electronic for ten to twenty years and the data of this study came entirely from 
electronic records. Dates of earlier diagnoses which were made in the days of paper 
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notes are often not transferred successfully. Outcome measures were adjusted for 
age of participants which would be likely to nullify any differences between the PP 
groups and the randomized control group with regard to age of diagnosis. There 
have been different phenotypes of asthma described partly based on age of onset 
[47] so we cannot exclude the possibility that probiotics have differential effects in 
different asthma phenotypes.  
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Appendix 7: Details of data-entry error and effects of differential loss to follow-up 
recorded in the Cochrane review relating to Cobo Sanz et al. 
 
The 2011 Cochrane systematic review found participants treated with probiotics had 
a reduced risk of antibiotic use for acute URTIs (RR 0.67 95% CI 0.45, 0.98) and for 
having ≥1 URTI (RR 0.55 95% CI 0.35, 0.86) [1]. The latter is a corrected figure 
which we recalculated using the original data from Cobo Sanz et al. [27] due to a 
data-entry error in the Cochrane review. However, this figure does make the same 
assumptions about how to handle the differential loss to follow up between 
intervention and control groups as the Cochrane review did for ≥3 URTI episodes. 
Those lost to follow up – 18.3% in the probiotic group, and 4.6% in the control group 
– are all assumed in the ITT analysis to have had no URTI during the trial period 
whereas there is no reason to suppose this was the reason for their loss to follow-up. 
This gives an impression of fewer URTI episodes in the probiotic group in this study 
which is entirely created by the differential loss to follow-up. If the data entry in the 
Cochrane review is corrected, with imputation of missing data from Cobo Sanz et al. 
assuming that the same proportion of dropouts within a group had URTIs as those 
for whom there were available data, then the pooled analysis for number of people 
experiencing ≥1 URTI becomes non-significant (OR 0.64, 95% CI 0.36, 1.12). The 
meta-analysis of antibiotic prescribing for URTIs does not include data from this 
paper and so is unaffected.  
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Appendix 8: Discussion of LRTI and asthma exacerbation outcome measures 
Studies of probiotics for preventing LRTI alone are scarce and our finding of no 
effect on LRTI is consistent with previous literature [19,29,48-50]. Our finding that 
probiotics do not prevent asthma exacerbations is also consistent with the small 
amount of prior work in this area [6].  
